Increase in prevalence of asthmatic and COPD patients’ worldwide, the rise in world aging population, surge in awareness concerning asthma and COPD diagnosis and management, and rapid technological advancement in developing asthma and COPD drugs have been responsible in driving the growth of global asthma and COPD drugs market. However, side-effects of such drugs, stringent regulatory requirements for the approval and commercialization of such drugs, and patient-expiry of the drugs themselves impede market growth. Conversely, the introduction of generic drugs for treating asthma and COPD is set to provide lucrative opportunities for emerging market players.
Get a sample report @ https://www.alliedmarketresearch.com/request-sample/311
The report also profiles key players involved in global asthma and COPD drugs market, such as
- GlaxoSmithKline (GSK) (U.K),
- Novartis AG (Switzerland),
- Merck & Co. (U.S),
- Abbott Laboratories (U.S),
- Boehringer Ingelheim (Germany),
- AstraZeneca (U.K),
- Roche Holding AG (Switzerland),
- Teva Pharmaceutical Industries(Israel),
- Vectura Group (U.K), and Pfizer Inc. (U.S).
Increase in incidence and prevalence of asthma and COPD, growing geriatric population, technological advancement in the treatment of asthma and COPD diseases, growth in initiatives implemented by the government and non-government associations around the Global are the factors that majorly drive the growth of this market. However, stringent government regulations for the product approval, patent expiry of branded drugs, and side effects associated with drugs restrict the market growth.
Global Asthma and COPD Drugs Market generated $38.9 billion in 2015 and is projected to attain $50.4 billion by 2022, growing at a CAGR of 3.7% from 2016 to 2022.
The report segments global asthma and COPD drugs market by diseases, medication class, and geography. Based on diseases, the report bifurcates the market into asthma or COPD. The asthma segment contributed over 65% to the global market revenue in 2015, owing to the rise in asthma prevalence due to change in lifestyle and an increase in geriatric population worldwide. However, the COPD segment is expected to grow at the fastest rate, registering a CAGR of 7.5%, during the forecast period.
Based on medication class, the market is sub-segmented into combination drugs, inhaled corticosteroids (ICS), short-acting beta agonists (SABA), long-acting beta agonists (LABA), leukotriene antagonists (LTA), anticholinergics, and others. While the combination drugs segment generated the largest revenue in 2016, the anticholinergics segment is expected to garner a remarkable 6.7% CAGR throughout 2022, due to increased and effective treatment of the disease. North America dominated the market share in 2015 and is expected to maintain this lead throughout the forecast period, due to an increase in asthma and COPD patients in this region and technological advancement in the treatment. However, with a CAGR of 5.1%, Asia-Pacific is anticipated to be the fastest-growing region through 2022, owing to a surge in the adoption rate of asthma and COPD treating drugs.
For the Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/311
They have adopted various strategies such as mergers & acquisitions, collaborations, partnerships, and others to gain a strong position in the industry.
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060